AbbVie Inc. (ABBV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AbbVie Inc. (ABBV) Healthcare & Pipeline Overview

AbbVie is a global pharmaceutical manufacturer headquartered in North Chicago, with a portfolio spanning immunology, oncology, neuroscience, gastroenterology, eye care, and other therapeutic areas. Its marketed products include HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, Botox therapeutic, and several established specialty medicines, supported by 55,000 employees.

What Is the Investment Thesis for ABBV?

AbbVie’s research profile centers on a diversified pharmaceutical portfolio rather than a single therapeutic category. Its marketed products cover immunology, oncology, gastroenterology, neuroscience, eye care, endocrinology, women's health, and migraine treatment, creating multiple product and disease-area exposure points. Key portfolio names include HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, Botox therapeutic, and Ubrelvy. Reported financial metrics provide the principal valuation and profitability framework in the supplied data: market capitalization is $388.43 billion, P/E is 106.1, gross margin is 74.1%, profit margin is 9.8%, dividend yield is 2.79%, and beta is 0.33. The data does not provide revenue, earnings, cash flow, growth rates, product-level sales, geographic mix, or analyst estimates, so specific earnings trajectories and valuation comparisons are Unknown. Potential value drivers include continued commercialization of the existing portfolio, demand across multiple therapeutic areas, research collaboration with Dragonfly Therapeutics, and the scale associated with 55,000 employees. Potential risks include product-specific demand changes, competition affecting individual therapies, regulatory or clinical uncertainty, and concentration in major products. The source data provides no patent-expiration dates, biosimilar timing, pipeline milestones, or financial guidance, so the timing and magnitude of these factors are Unknown.

Based on FMP financials and quantitative analysis

ABBV Key Highlights

Market capitalization of $468B, indicating AbbVie is a large publicly traded healthcare company.

• Gross margin of 74.1%, reflecting the reported profitability of AbbVie’s pharmaceutical operations.
• Profit margin of 9.8%, providing a reported measure of net profitability based on the supplied fundamentals.
• P/E ratio of 106.1, a valuation metric that should be interpreted alongside unavailable earnings-growth, cash-flow, and product-level data.
• Dividend yield of 2.79% and beta of 0.33, combining a reported shareholder-distribution measure with comparatively low reported market sensitivity.

Who Are ABBV's Competitors?

ABBV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABBV's Key Strengths?

Diversified pharmaceutical portfolio across multiple therapeutic areas.

• Worldwide operations and a workforce of 55,000 employees.
• Reported gross margin of 74.1%.
• Several established and identifiable flagship products, including SKYRIZI, RINVOQ, IMBRUVICA, and VENCLEXTA.

What Are ABBV's Weaknesses?

Reported profit margin of 9.8% is materially below the reported gross margin, although the source does not explain the difference.

• P/E ratio of 106.1 indicates a high reported earnings multiple without accompanying growth or cash-flow context.
• The supplied data does not provide revenue, earnings, cash flow, geographic mix, or product-level sales.
• The source does not quantify the contribution or concentration of individual products.

What Could Drive ABBV Stock Higher?

ABBV catalyst: Commercial activity across AbbVie’s immunology portfolio, including HUMIRA, SKYRIZI, and RINVOQ, serving the specified autoimmune and inflammatory indications.

• Continued utilization of oncology products IMBRUVICA and VENCLEXTA for the specified chronic lymphocytic leukemia and small lymphocytic lymphoma populations.
• Diversification across Ubrelvy, CREON, Synthroid, Linzess/Constella, Botox therapeutic, eye-care products, and neuroscience therapies.
• Research collaboration with Dragonfly Therapeutics, Inc., with collaboration objectives, milestones, and timing Unknown.
• Worldwide pharmaceutical operations supported by a reported workforce of 55,000 employees.

What Are the Key Risks for ABBV?

Rich valuation — a P/E of 106.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Product-specific competition could affect demand for AbbVie’s medicines; the source does not identify competitors by product or quantify exposure.
• Regulatory or clinical developments could affect pharmaceutical products, although no specific pending decisions, trial results, or probabilities are provided.
• Changes in demand across AbbVie’s diverse therapeutic categories could affect performance; product-level sales and trends are Unknown.
• Manufacturing, distribution, or worldwide market-access challenges could affect the company, with no specific incidents or exposures supplied.
• The reported P/E ratio of 106.1 creates valuation sensitivity to earnings outcomes, while growth, cash-flow, and guidance data are not provided.

What Are the Growth Opportunities for ABBV?

• Growth opportunity 1: AbbVie can continue developing the commercial reach of its immunology portfolio, which includes HUMIRA, SKYRIZI, and RINVOQ. SKYRIZI addresses moderate to severe plaque psoriasis in adults, while RINVOQ addresses moderate to severe active rheumatoid arthritis in adult patients. The source does not provide current sales, patient counts, market sizes, geographic penetration, or launch schedules, so the size of the opportunity and timeline are Unknown. The specific opportunity is continued demand and lifecycle development across multiple immune-mediated conditions already represented in AbbVie’s portfolio.
• Growth opportunity 2: Oncology provides another potential expansion area through IMBRUVICA and VENCLEXTA. IMBRUVICA is used for adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, while VENCLEXTA is a BCL-2 inhibitor used for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The source does not identify additional indications, clinical-stage programs, market sizes, competitive shares, or regulatory milestones. Accordingly, the addressable market and timeline are Unknown. Growth could come from continued use, geographic availability, or further development of these oncology products, subject to facts not supplied here.
• Growth opportunity 3: AbbVie’s established specialty portfolio creates potential for growth across several non-immunology categories. Products include Ubrelvy for migraine with or without aura in adults, CREON for exocrine pancreatic insufficiency, Synthroid for hypothyroidism, Linzess and Constella for constipation-related conditions, and ORILISSA for endometriosis pain. The source does not provide product revenue, prescription trends, market sizes, or future commercialization dates. Those figures and timelines are Unknown. The opportunity is portfolio-wide utilization across distinct patient populations and therapeutic needs rather than dependence on a single disease area.
• Growth opportunity 4: AbbVie may have opportunity to broaden its eye-care and neuroscience presence through products including Restasis, Lumigan, Ganfort, Alphagan, Combigan, Duopa, and Duodopa. Restasis is intended to increase tear production, while the eye-care products address elevated intraocular pressure and the Duopa and Duodopa products treat Parkinson’s disease. No market-size estimates, product growth rates, geographic expansion plans, or pipeline milestones are provided. The timing is therefore Unknown. Continued commercialization of these products could provide additional diversification within AbbVie’s worldwide pharmaceutical business.
• Growth opportunity 5: Research and external collaboration may support future portfolio development. AbbVie has a research collaboration with Dragonfly Therapeutics, Inc., and already operates across numerous therapeutic categories with 55,000 employees. The source does not describe the collaboration’s targets, development stage, financial terms, expected products, probability of success, or milestone dates. Market size and timeline are Unknown. The specific opportunity is the possibility that research capabilities and collaboration activity expand AbbVie’s future treatment portfolio, although no outcome or future product can be stated from the supplied data.

What Are ABBV's Competitive Advantages?

• A diversified portfolio spanning numerous therapeutic areas and patient populations.
• Recognized marketed products including HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, Botox therapeutic, and Ubrelvy.
• Reported 74.1% gross margin, reflecting a high-margin pharmaceutical operating profile in the supplied data.
• Scale associated with 55,000 employees and worldwide pharmaceutical operations.
• Research capabilities and collaboration activity, including the relationship with Dragonfly Therapeutics, Inc.

What Does ABBV Do?

AbbVie Inc. was incorporated in 2012 and is headquartered in North Chicago, Illinois. The company discovers, develops, manufactures, and sells pharmaceuticals worldwide. The provided information does not describe the specific founding transaction, predecessor organization, or original corporate structure, so those details are Unknown. Since incorporation, AbbVie has developed a broad commercial portfolio spanning immunology, oncology, neuroscience, eye care, gastroenterology, endocrinology, women's health, and other treatment categories. The company's products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, used to treat moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adults. Its oncology portfolio includes IMBRUVICA, used for adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, and VENCLEXTA, a BCL-2 inhibitor used to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. AbbVie also offers MAVYRET for chronic hepatitis C virus genotype 1-6 infection. Additional products address exocrine pancreatic insufficiency through CREON; hypothyroidism through Synthroid; irritable bowel syndrome with constipation and chronic idiopathic constipation through Linzess and Constella; and several indications through Lupron. Botox therapeutic is also part of the portfolio. In women's health and neuroscience, AbbVie offers ORILISSA for endometriosis pain and Duopa or Duodopa for Parkinson's disease. Eye-care products include Lumigan, Ganfort, Alphagan, Combigan, and Restasis, while Ubrelvy is used to treat migraine with or without aura in adults. AbbVie operates in worldwide pharmaceutical markets, although the provided data does not specify revenue by geography, manufacturing footprint, or country-level market share. The company reports 55,000 employees and has a research collaboration with Dragonfly Therapeutics, Inc. Its competitive position is represented in the supplied peer set by Johnson & Johnson, UnitedHealth Group Incorporated, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S. AbbVie is publicly traded under ticker ABBV. Reported financial metrics include a $468B market capitalization, 106.06 P/E ratio, 9.8% profit margin, 74.1% gross margin, 0.33 beta, and 2.79% dividend yield.

What Products and Services Does ABBV Offer?

• Discover and develop pharmaceutical treatments across multiple therapeutic areas.
• Manufacture and sell medicines in worldwide markets.
• Offer immunology products including HUMIRA, SKYRIZI, and RINVOQ.
• Provide oncology therapies including IMBRUVICA and VENCLEXTA.
• Sell treatments for hepatitis C, migraine, gastrointestinal conditions, hypothyroidism, and pancreatic insufficiency.
• Market eye-care products for conditions involving tear production and elevated intraocular pressure.
• Offer therapies for Parkinson’s disease, endometriosis, prostate cancer, and other stated indications.
• Conduct research and maintain a collaboration with Dragonfly Therapeutics, Inc.

How Does ABBV Make Money?

• AbbVie generates pharmaceutical revenue by discovering, developing, manufacturing, and selling branded therapies.
• Revenue is derived from products spanning immunology, oncology, gastroenterology, neuroscience, eye care, endocrinology, women's health, migraine, and other treatment categories.
• The company sells therapies addressing specified diseases and conditions in worldwide markets.
• Research collaborations, including the relationship with Dragonfly Therapeutics, Inc., form part of its broader pharmaceutical development activities.

What Industry Does ABBV Operate In?

AbbVie operates in the Drug Manufacturers - General industry within the Healthcare sector. Its portfolio spans immunology, oncology, gastroenterology, neuroscience, eye care, endocrinology, women's health, and migraine treatment. The supplied information does not provide pharmaceutical industry growth rates, total addressable market sizes, market shares, or competitive sales data, so those figures are Unknown. The stated peer group includes Johnson & Johnson, UnitedHealth Group Incorporated, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S. These companies provide a reference set for institutional comparison, although the source does not specify how each peer overlaps with AbbVie by product, therapeutic area, or business model.

Who Are ABBV's Key Customers?

• Patients using AbbVie therapies for autoimmune, oncological, neurological, gastrointestinal, ophthalmic, endocrine, and other conditions.
• Healthcare professionals and providers who prescribe or administer AbbVie medicines.
• Healthcare systems, pharmacies, distributors, and other pharmaceutical-market participants.
• Patients and providers in worldwide markets, with specific geographic customer segmentation Unknown.

AbbVie Inc. (ABBV) Valuation Context

Valued at $468B, ABBV is classified as a mega-cap stock. Relative to its peer group, ABBV's quantitative score of 82/100 is above the peer average of 70/100.

ABBV Revenue & Earnings Trend

In Q2 2026, ABBV generated $16.99B in top-line revenue, marking a sequential increase of 13.3%. The company recorded net income of $3.61B, with diluted EPS of $2.04. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, ABBV averaged $0.89 in diluted EPS.

Company Profile

AbbVie Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in North Chicago, US. The company is led by CEO Robert A. Michael. ABBV has traded publicly since 2013.

Return on equity for AbbVie Inc. stands at 68.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.7%, showing how much profit it generates from its asset base. ABBV trades at a trailing price-to-earnings ratio of 106.06, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.80 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.

AbbVie Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.50 places it in the grey zone, a middle ground that warrants monitoring.

AbbVie Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 0.9% below estimates on average.

Wall Street analysts project AbbVie Inc. revenue of about $67.49B for fiscal 2026, with EPS near $14.05. The estimate reflects 15 contributing analysts.

Over the past six months, AbbVie Inc. insiders filed 15 SEC Form 4 transactions — 0 sales and 15 purchases. On net that is roughly 13K shares acquired (about $98K) — insiders putting money in tends to read as conviction.

ABBV Financials

ABBV Latest News

ABBV Analyst Consensus

ABBV MoonshotScore

Latest AbbVie Inc. Analysis

What Investors Ask About AbbVie Inc. (ABBV) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources